• Politics
  • Business
  • World
  • Science
  • Startup
  • Health
  • Travel
  • Economy
  • Top Story
Aryavarth News
  • Home
  • Politics
  • City News
  • Top Story
  • Editorial
No Result
View All Result
Aryavarth News
No Result
View All Result

SII partner Novavax’s Covid-19 shot 90% effective

The vaccine NVX-CoV2373 is already being locally manufactured by the company's India partner Pune-based Serum Institute of India (SII) under the brand name Covovax.

SII partner Novavax’s Covid-19 shot 90% effective
100
SHARES
385
VIEWS
Share on WhatsappShare on FacebookShare on TwitterShare on Telegram

Washington,(Aryavarth) US-based biotechnology company Novavax’s protein-based vaccine has shown overall 90 per cent efficacy against Covid-19, results of Phase-3 trials have shown.

The vaccine NVX-CoV2373 is already being locally manufactured by the company’s India partner Pune-based Serum Institute of India (SII) under the brand name Covovax.

In the US-based Phase-3 trials, NVX-CoV2373 also demonstrated 100 per cent protection against moderate and severe disease.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional Covid-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe Covid-19 infection,” said Stanley C Erck, President and Chief Executive Officer, Novavax, in a statement.

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines,” Erck added.

In August 2020, Novavax and SII announced an agreement under which the US biotechnology company had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.

In March 2021, CEO Adar Poonawalla said Covovax will be launched by September this year.

“Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India,” said Adar Poonawalla.

“Hope to launch by September 2021!” the CEO of the world’s biggest Covid-19 vaccine maker said.

The US-based Phase-3 trials began in December 2020 and enrolled 29,960 participants across 119 sites in the US and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.

The study “confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile”, said Gregory M Glenn, MD, President of Research and Development, Novavax.

The company will file for regulatory authorisations in the third quarter. After receiving the approvals, Novavax will reach a manufacturing capacity of 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth quarter of 2021, the statement said.

NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein and is formulated with Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralising antibodies. It contains purified protein antigen and can neither replicate, nor can it cause Covid-19.

The vaccine can be stored at 2 to 8 degrees Celsius, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.

The two-shot vaccine is also being evaluated in Phase 3 trials in the UK that demonstrated efficacy of 96.4 per cent against the original virus strain, 86.3 per cent against the B117 (Alpha) variant and 89.7 per cent overall.

It is also being tested in two ongoing Phase 2 studies that began in August 2020: A Phase 2b trial in South Africa that demonstrated 55 per cent efficacy overall in HIV-negative participants and 48.6 per cent efficacy against the B1351 (Beta) variant, and a Phase 1/2 study in the US and Australia.

The company is also conducting trials in adolescents between ages 12 and 18.

Tags: #covidvaccine
SendShare54Tweet34Share
    • Trending
    • Comments
    • Latest
    Guru Gobinds son bricked alive and then killed

    Crores of Hindus Were killed by Islamic Rulers: Hindu Genocide Not Recorded In History

    August 10, 2020
    Pakistan Behind removal of Punjab CM:  Dr Subramanian Swamy

    Pakistan Behind removal of Punjab CM: Dr Subramanian Swamy

    September 20, 2021
    Lenovo under US scanner for spying for China

    Lenovo’s Links to China Government Under Scrutiny For Spying

    July 22, 2020
    Republic TV and R Bharat get a clean chit in Television Rating Points (TRP) scam

    Republic TV and R Bharat get a clean chit in Television Rating Points (TRP) scam

    3
    Today’s Newspaper – 17 August 2022

    Today’s Newspaper – 17 August 2022

    2
    Today’s Newspaper – 10 August 2022

    Today’s Newspaper – 10 August 2022

    1
    WHO and the Ministry of Ayush to host the first-ever Global Summit on Traditional Medicine

    Only Positive Step In G20 Summit Was The Admission Of African Union As A Permanent Member

    September 15, 2023
    Singapore invents tech to detect COVID-19 virus the air

    India Rises as Global Leader in Medical Textiles Amid COVID-19 Pandemic

    September 15, 2023
    Improving Healthcare for All

    CSIR-NIScPR and KAMP Host Workshop to Boost Science Communication in India

    September 15, 2023
    Aryavarth News

    Copyright © 2022 Aryavarth Publication Pvt Ltd.

    Navigate Site

    • About
    • Advertise
    • Privacy & Policy
    • Contact

    Follow Us

    No Result
    View All Result
    • Politics
    • Business
    • World
    • Science
    • Startup
    • Health
    • Travel
    • Economy
    • Top Story

    Copyright © 2022 Aryavarth Publication Pvt Ltd.

    This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.